Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Nonalcoholic steatohepatitis. Three case reports].

Martin V Eivindson1, Stephen Hamilton-Dutoit, Henning Grønbaek

  • 1Medicinsk Afdeling V, Arhus Kommunehospital, DK-8000 Arhus V.

Ugeskrift for Laeger
|April 8, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alpha 2A adrenergic receptor antagonism reduces fibrosis, inflammation and portal hypertension in models of chronic liver disease.

JHEP reports : innovation in hepatology·2026
Same author

Quality of Life in Patients With Primary Sclerosing Cholangitis.

Gastro hep advances·2026
Same author

Primary Biliary Cholangitis Increases Mortality Irrespective of Presence or Absence of Cirrhosis.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Biomarker-directed aptamer panels for diagnosis and differentiation of neuroendocrine tumors.

Journal of neuroendocrinology·2026
Same author

Development and validation of the A-TANGO organ failure score for acute-on-chronic liver failure in global cohorts.

Journal of hepatology·2026
Same author

Quality of Life in Patients With Variant Syndromes of Autoimmune Liver Diseases-A Cross-Sectional Multicentre Study.

Liver international : official journal of the International Association for the Study of the Liver·2026

Non-alcoholic steatohepatitis (NASH), a severe form of non-alcoholic fatty liver disease (NAFLD), can lead to serious liver damage. This summary highlights key clinical and histopathological features of NASH progression.

Area of Science:

  • Hepatology
  • Internal Medicine
  • Pathology

Background:

  • Non-alcoholic fatty liver disease (NAFLD) affects a significant portion of the population.
  • A subset of NAFLD patients develop Non-alcoholic steatohepatitis (NASH).
  • NASH is closely linked to metabolic syndrome, characterized by insulin resistance and obesity.

Observation:

  • NASH progression can result in severe liver conditions.
  • Clinical and histopathological changes are characteristic of NASH.
  • Case studies illustrate the presentation and progression of NASH.

Findings:

  • NASH can advance to liver fibrosis and cirrhosis.
  • Advanced NASH may lead to chronic hepatic failure.
  • Liver transplantation may be required in end-stage NASH.

Related Experiment Videos

Implications:

  • Understanding NASH progression is crucial for patient management.
  • Early identification of NASH is vital to prevent irreversible liver damage.
  • Further research into NASH pathogenesis and treatment is warranted.